



Press Release

BSE Scrip Code: 506943

NSE Symbol: JBCHEPHARM

Mumbai, August 6, 2012:

Unaudited Financial Results for Q 1- 2012-13

J.B. Chemicals & Pharmaceuticals Ltd. (JBCPL) today announced its standalone unaudited financial results for the quarter ended on June 30, 2012. The financial results for the quarter are strictly not comparable with the results of the corresponding quarter in the previous year due to sale of Russia-CIS OTC business on July 14, 2011. The highlights of these results are as under.

(Rs. in crores)

Particulars	Q1-2012-13	Q1-2011-12
Revenue from operations (Net)	184.85	177.44
Other Operating income	4.89	5.12
Other Income	2.70	4.18
Total Revenue	192.44	186.74
Profit from ordinary activities after finance cost but before exchange fluctuation translation loss	15.42	29.25
Profit from ordinary activities before tax	5.81	26.88
Profit from ordinary activities after tax	4.31	19.05
EPS (Rs.)	0.51	2.25
Book value per share (Rs.)	113.11	

The overall sales for the quarter were higher despite sale of the Russia-CIS OTC business in Q2 last year.

The company is fully focused on the domestic formulations business. For the quarter, the growth was lower than expected. While the newer products have shown reasonable growth, the older matured seasonal products have shown poor performance. Domestic business will continue to be the main driver for the coming years for the company.

The exports to Rest of the World (RoW) markets achieved impressive growth over the corresponding quarter in the previous year and this business is expected to

maintain good momentum through the year. The company's focus on the US market, contract manufacturing and the generic business has shown good results. The company continues to focus on these 3 business opportunities to maximize the potential.

The prescription products sales in Russia-CIS were lower. After the sales of OTC business, we are recreating the necessary infrastructure. This will take about 6 months.

The operating performance for the quarter before factoring exchange fluctuation related losses was reasonably satisfactory; however, the exchange fluctuation related losses impacted the profits for the quarter.

Russia-CIS OTC business that the company sold last year was very profitable for the company. It will take some time before we can achieve the similar level of profit from the other businesses. The company is seized of the issues and is working to address the same.

About JBCPL:

JBCPL, one of India's leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and API's. JBCPL exports to many countries worldwide with a strong presence in Russia, Ukraine, CIS countries and South Africa. The Company continues to invest in growing its share in the regulated markets in USA, Europe, Australia and Brazil. JBCPL has a strong R & D set-up for development of NDDS formulations, filing of DMF's and ANDA's. Its State-of-the-Art Manufacturing facilities are approved by renowned international regulatory authorities.

For more information on JBCPL visit our website at www.jbcpl.com. For more details, you may contact:

M.C. Mehta
Company Secretary- General Manager
J. B. Chemicals & Pharmaceuticals Ltd.
91 22 3045 1311

-- x --

Forward Looking Statements:

This Press Release may contain Forward Looking Statements regarding future events and future performance of J.B. Chemicals & Pharmaceuticals Ltd. that involve risks and uncertainties that could cause actual results to differ materially from those that may be indicated by such statements.